Lab work is "high mix, low volume," like driving, making it hard to automate. Traditional automation is like a subway: efficient but inflexible. AI enables "autonomous" labs, akin to Waymo cars, that handle the vast variability of experiments, which constitutes 99% of lab work.

A core step in Elon Musk's scaling algorithm is to 'Automate Last.' Tesla discovered that automating a process before it's manually optimized is a recipe for disaster. The Model 3 production crisis was only solved when they abandoned the over-automated line and started building cars by hand in a tent.

Instead of pursuing 100% automation, Lila's system treats complex manual tasks as API calls routed to human technicians. This pragmatic approach keeps humans 'below the API line,' seamlessly integrating necessary manual work into a software-driven workflow without halting automation.

The platform reduces labor needs by 90%. While this cuts costs, the primary benefit is overcoming the industry's severe shortage of highly skilled scientists. This talent scarcity is the true bottleneck to scaling cell therapy production, making automation a necessity for growth, not just an efficiency play.

The biotech industry often believes its processes require unique, specialized robots. In reality, well-proven robotics from industrial and logistics sectors are applicable. The key is thoughtful system design and adaptation (e.g., sterilization, end effectors), not reinventing core technology.

Despite labs being human-centric, humanoid robots are a poor solution. The primary task is moving samples, which specialized tracks do better. Biology, like chip manufacturing, is a microscopic discipline where the goal is to remove human-scale limitations, not replicate them with robots.

Enterprises with existing customers cannot afford the "Waymo" approach of building a fully autonomous system in secret before launch. Instead, they should follow the "Tesla" model: iteratively automate segments of their products, keeping humans in the loop while gradually building towards greater autonomy.

While automation helps reduce the cost of the embryology lab portion of IVF, its most significant impact is enabling clinics in smaller markets. An automated lab lowers the high upfront capital and specialized staffing needs, making IVF viable in areas that previously couldn't support a full-scale clinic.

Unlike pre-programmed industrial robots, "Physical AI" systems sense their environment, make intelligent choices, and receive live feedback. This paradigm shift, similar to Waymo's self-driving cars versus simple cruise control, allows for autonomous and adaptive scientific experimentation rather than just repetitive tasks.